TTOO News and Press, T2 Biosystems Inc. From 05/06/22

T2 Biosystems (NASDAQ:TTOO) stock fell May 6, a day after it reported its Q1 results. Q1 revenue rose +4% Y/Y to $7.23M. The company said product revenue declined 17% Y/Y to 3.84M, mainly due to decreased COVID-19 test sales. Meanwhile, contribution revenue grew +47% Y/Y to $3.39M. Net l...

T2 Biosystems, Inc. (TTOO) Q1 2022 Earnings Conference Call May 05, 2022, 04:30 PM ET Company Participants Malcolm MacLeod - IR Philip Taylor - Gilmartin Group John Sperzel - Chairman and CEO John Sprague - CFO Brett Giffin - Chief Commercial Officer Conference Call Participants Benjamin Hayn...

T2 Biosystems press release (NASDAQ:TTOO): Q1 GAAP EPS of -$0.10 misses by $0.02. Revenue of $7.23M (+3.3% Y/Y) beats by $0.53M. Outlook: The Company continues to expect full year 2022 total revenue of $28.0 to $31.0 million, including product revenue of $16.0 to $17.0 million and research co...

T2 Biosystems (TTOO) on Thursday received a Nasdaq notice regarding its failure to comply with the $1 minimum bid price rule for continued listing. TTOO filed an appeal and hearing request to stay the delisting of its shares. Nasdaq informed TTOO that the delisting action has been stayed and ...

LEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the first quarter ended March 31, 2022....

LEXINGTON, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on May 5, 2022 it received a letter from The Nasdaq Stock Market informing the Company...

LEXINGTON, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the formation of its Scientific Advisory Board (SAB), comprising leading clinicians and r...

T2 Biosystems (NASDAQ:TTOO) on Wednesday said it had applied for a Breakthrough Device designation from the U.S. FDA for its T2Biothreat Panel product. TTOO stock +5.1% to $0.42 in premarket trade. The FDA's Breakthrough Device program aims to speed up the development and access to medical de...

LEXINGTON, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has submitted an application with the U.S. Food and Drug Administration (FDA) for...

LEXINGTON, Mass., April 21, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2022 after market close on Th...